In a randomized, double-blind study, Lammers et al. compared the pharmacokinetics, efficacy, safety, and immunogenicity of PF-05280014 and the reference product trastuzumab (Herceptin) from the EU (trastuzumab-EU) in patients with operable HER2+ BC. Here, ERBB2 is linked to breast cancer.